SynthesisJournal of Zhejiang University. Science. B2012
Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis.
Synthesis in Journal of Zhejiang University. Science. B, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis.African health sciences · 2020Pooled it
- The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.PloS one · 2015Pooled it
- Can Phagocytosis, Neutrophil Extracellular Traps, and IFN-α Production in Systemic Lupus Erythematosus Be Simultaneously Modulated? A Pharmacological Perspective.International journal of molecular sciences · 2026Review
- Rituximab Treatment in Lupus Nephritis Resistant to Conventional Therapy: A Single-Centre Experience.Mediterranean journal of rheumatology · 2025Article
- Opportunities and limitations of B cell depletion approaches in SLE.Nature reviews. Rheumatology · 2025Review
- Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.Mediterranean journal of rheumatology · 2024Review
- Infections in Patients with Systemic Lupus Erythematosus: The Contribution of Primary Immune Defects Versus Treatment-Induced Immunosuppression.European journal of rheumatology · 2023Article
- Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus.Annals of the rheumatic diseases · 2019Article
- Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.Experimental and therapeutic medicine · 2019Article
- Changing paradigms in the treatment of systemic lupus erythematosus.Lupus science & medicine · 2019Article
- Systemic lupus erythematosus: Diagnosis and clinical management.Journal of autoimmunity · 2019Review
- Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.Journal of neurology · 2016Observational
- Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide.BMJ case reports · 2015Article
- Biologics in dermatology: an integrated review.Indian journal of dermatology · 2014Review
- Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus.Autoimmune diseases · 2014Article
- Rituximab and lupus--a promising pair?Current rheumatology reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the efficacy and safety of rituximab therapy for systemic lupus erythematosus (SLE).
methodsWe searched for randomized controlled trails and observational studies that evaluated the effect of rituximab based on the systemic lupus erythematosus disease activity index (SLEDAI), British Isles lupus assessment group index (BILAG), urine protein levels, and the prednisolone dose, and had adequate data to calculate the mean, standard deviation (SD), and 95% confidence intervals, and to systematically review and meta-analyze observational studies with fixed effects model or random effects model.
resultsWe included 2 randomized controlled studies and 19 observational clinical studies. We summarized the data from the 19 observational studies, analyzed the heterogeneity of the literature, and then used fixed effect model or random effect model for statistical analysis. The SLEDAI, BILAG, and urine protein levels and the prednisolone dosage were decreased after rituximab treatment, and the decreases in the BILAG, urine protein levels, and the prednisolone dose were found to be significant (P<0.05), when compared with baseline level. Rituximab's adverse effects generally could be controlled with an effective dosing regimen.
conclusionsAlthough there are still controversies about rituximab's treatment on SLE, but our study had showed that rituximab had favorable effects on refractory lupus. The long-term efficacy and safety of rituximab require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.